Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study.

导出 OA

翻译打印收藏纠错

作者： Pallawi,Torka ^[1] ; Othman S,Akhtar ^[1] ; Nishitha M,Reddy ^[2] ; Bora E,Baysal ^[1] ; Angela,Kader ^[1] ; Adrienne,Groman ^[1] ; Jenna,Nichols ^[1] ; Cory,Mavis ^[1] ; Joseph D,Tario ^[1] ; AnneMarie W,Block ^[1] ; Sheila N J,Sait ^[1] ; Paola,Ghione ^[1] ; Suchitra,Sundaram ^[3] ; Eugene R,Przespolewski ^[1] ; Alice,Mohr ^[1] ; Ian,Lund ^[1] ; Jessica,Kostrewa ^[1] ; Kenneth,McWhite ^[1] ; Joseph,DeMarco ^[1] ; Michael,Johnson ^[1] ; Andrea,Darrall ^[1] ; Rosh-Neke,Thomas-Talley ^[1] ; Paul K,Wallace ^[1] ; Vishala,Neppalli ^[4] ; Alan,Hutson ^[1] ; Francisco J,Hernandez-Ilizaliturri ^[1]

作者单位： Roswell Park Comprehensive Cancer Center, Buffalo, New York. ^[1] Vanderbilt University Medical Center, Nashville, Tennessee. ^[2] Icahn School of Medicine at Mount Sinai, New York, New York. ^[3] University of Manitoba, Winnipeg, Manitoba, Canada. ^[4]

关键词 CD20 MIPI score monoclonal antibody p53 survival outcomes

主题词成年人(Adult);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);人类(Humans);淋巴瘤, 膜细胞(Lymphoma, Mantle-Cell);中年人(Middle Aged);肿瘤, 残余(Neoplasm, Residual)

DOI 10.1002/cncr.34106

PMID 35157306

发布时间 2023-04-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交